A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors.
- Who it may be relevant to
- Registry conditions: Colorectal Cancer Metastatic. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in the Treatment of Microsatellite Stable Advanced Colorectal Cancer
Overview
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.
Interventions
- Drug Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Primary outcome measures
- Progression-free survival(PFS) [Time frame: 2 years]
Secondary outcome measures (4)
- Objective Response Rate（ORR） [Time frame: 2 years]
- Clinical Benefit Rate (CBR) [Time frame: 2 years]
- Disease Control Rate （DCR） [Time frame: 2 years]
- Overall survival (OS) [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Aged≥18 years
- Histology-confirmed metastatic CRC (mCRC);
- ECOG 0\~2
- At least one efficacy evaluation
- Life expectancy of at least 3 months.
Exclusion criteria
- Lack of follow-up data.
- Chidamide stopped after less than two cycles.
- Serious comorbidities that interfere with the efficacy or safety analysis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06682247 · CSIIT-Q88